$QURE
uniQure N.V.

2021 Q2 Form 10-Q Financial Statement

#000155837021009246 Filed on July 26, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2020 Q2 2020 Q1
Revenue $463.9M $1.535M $104.0K
YoY Change 30119.41% -37.95% -90.85%
Cost Of Revenue $23.18M
YoY Change
Gross Profit $440.7M
YoY Change
Gross Profit Margin 95.0%
Selling, General & Admin $17.30M $11.51M $9.072M
YoY Change 50.28% 46.26% 12.46%
% of Gross Profit 3.93%
Research & Development $32.75M $28.40M $26.01M
YoY Change 15.3% 17.58% 26.66%
% of Gross Profit 7.43%
Depreciation & Amortization $1.807M $1.780M $1.730M
YoY Change 1.52% 7.88% 10.19%
% of Gross Profit 0.41%
Operating Expenses $50.05M $39.91M $35.09M
YoY Change 25.39% 24.63% 22.66%
Operating Profit $398.0M -$38.21M -$34.46M
YoY Change -1141.69% 30.26% 25.3%
Interest Expense $1.902M $970.0K $975.0K
YoY Change 96.08% 3.52% 1.88%
% of Operating Profit 0.48%
Other Income/Expense, Net $226.0K $500.0K $339.0K
YoY Change -54.8% 44.09% -2.87%
Pretax Income $402.7M -$42.55M -$28.00M
YoY Change -1046.45% 35.52% 0.82%
Income Tax $3.258M $0.00
% Of Pretax Income 0.81%
Net Earnings $399.5M -$42.55M -$28.00M
YoY Change -1038.82% 35.51% 0.82%
Net Earnings / Revenue 86.12% -2771.99% -26922.12%
Basic Earnings Per Share $8.68 -$0.96
Diluted Earnings Per Share $8.51 -$0.96 -$632.3K
COMMON SHARES
Basic Shares Outstanding 46.04M 44.39M 44.25M
Diluted Shares Outstanding 46.93M 44.39M

Balance Sheet

Concept 2021 Q2 2020 Q2 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $677.3M $314.3M $342.0M
YoY Change 115.5% 70.72% 63.79%
Cash & Equivalents $677.3M $314.3M $342.0M
Short-Term Investments
Other Short-Term Assets $14.19M $1.066M $1.576M
YoY Change 1231.05% 83.79% -60.6%
Inventory
Prepaid Expenses $10.86M $4.082M $5.738M
Receivables $2.705M $200.0K $300.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $694.2M $319.6M $349.6M
YoY Change 117.19% 69.53% 63.98%
LONG-TERM ASSETS
Property, Plant & Equipment $38.37M $29.30M $27.74M
YoY Change 30.95% 4.43% -40.35%
Goodwill $525.0K $496.0K $486.0K
YoY Change 5.85% -1.39%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.760M $2.700M $2.900M
YoY Change 113.33% -6.9% 0.0%
Total Long-Term Assets $90.04M $65.71M $64.64M
YoY Change 37.03% 1.81% 15.85%
TOTAL ASSETS
Total Short-Term Assets $694.2M $319.6M $349.6M
Total Long-Term Assets $90.04M $65.71M $64.64M
Total Assets $784.3M $385.3M $414.2M
YoY Change 103.52% 52.26% 53.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $16.82M $4.942M $4.989M
YoY Change 240.29% 9.26% 42.54%
Accrued Expenses $23.53M $13.25M $9.507M
YoY Change 77.55% 79.88% -14.35%
Deferred Revenue $6.153M $6.732M
YoY Change -14.81%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change
Total Short-Term Liabilities $46.10M $29.84M $27.13M
YoY Change 54.47% 27.7% 21.11%
LONG-TERM LIABILITIES
Long-Term Debt $70.78M $35.37M $36.21M
YoY Change 100.1% -1.15% 1.71%
Other Long-Term Liabilities $3.247M $464.0K $524.0K
YoY Change 599.78% 17.47% -99.03%
Total Long-Term Liabilities $104.6M $90.00M $91.97M
YoY Change 16.18% -7.84% 2.87%
TOTAL LIABILITIES
Total Short-Term Liabilities $46.10M $29.84M $27.13M
Total Long-Term Liabilities $104.6M $90.00M $91.97M
Total Liabilities $150.7M $119.8M $119.1M
YoY Change 25.72% -0.98% 6.43%
SHAREHOLDERS EQUITY
Retained Earnings -$426.8M -$730.3M -$687.7M
YoY Change -41.55% 22.8%
Common Stock $2.788M $2.692M $2.683M
YoY Change 3.57% 15.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $633.6M $265.5M $295.1M
YoY Change
Total Liabilities & Shareholders Equity $784.3M $385.3M $414.2M
YoY Change 103.52% 52.26% 53.99%

Cashflow Statement

Concept 2021 Q2 2020 Q2 2020 Q1
OPERATING ACTIVITIES
Net Income $399.5M -$42.55M -$28.00M
YoY Change -1038.82% 35.51% 0.82%
Depreciation, Depletion And Amortization $1.807M $1.780M $1.730M
YoY Change 1.52% 7.88% 10.19%
Cash From Operating Activities $416.5M -$29.99M -$32.95M
YoY Change -1488.72% 23.82% 24.64%
INVESTING ACTIVITIES
Capital Expenditures -$2.311M -$1.720M $677.0K
YoY Change 34.36% 43.33% 189.32%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$2.311M -$1.720M -$2.890M
YoY Change 34.36% 43.33% 134.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.010M
YoY Change -53.63%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.508M 2.540M 1.010M
YoY Change -1.26% 370.37% -62.29%
NET CHANGE
Cash From Operating Activities 416.5M -29.99M -32.95M
Cash From Investing Activities -2.311M -1.720M -2.890M
Cash From Financing Activities 2.508M 2.540M 1.010M
Net Change In Cash 416.7M -29.17M -35.78M
YoY Change -1528.43% 17.24% 39.61%
FREE CASH FLOW
Cash From Operating Activities $416.5M -$29.99M -$32.95M
Capital Expenditures -$2.311M -$1.720M $677.0K
Free Cash Flow $418.8M -$28.27M -$33.63M
YoY Change -1581.38% 22.81% 26.09%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44777799
dei Entity Central Index Key
EntityCentralIndexKey
0001590560
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
46050250
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity Registrant Name
EntityRegistrantName
uniQure N.V.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
P7
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.05
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.05
us-gaap Investment Income Interest
InvestmentIncomeInterest
77000
us-gaap Investment Income Interest
InvestmentIncomeInterest
903000
CY2021Q2 us-gaap Interest Expense
InterestExpense
1902000
CY2020Q2 us-gaap Interest Expense
InterestExpense
970000
us-gaap Interest Expense
InterestExpense
3453000
us-gaap Interest Expense
InterestExpense
1945000
CY2021Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
6583000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
957000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
191000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2206000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
147000
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36294
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Address Address Line1
EntityAddressAddressLine1
Paasheuvelweg 25
dei Entity Address City Or Town
EntityAddressCityOrTown
1105 BP Amsterdam
dei Entity Address Country
EntityAddressCountry
NL
dei City Area Code
CityAreaCode
31
dei Local Phone Number
LocalPhoneNumber
20-240-6000
dei Security12b Title
Security12bTitle
Ordinary Shares, par value €0.05
dei Trading Symbol
TradingSymbol
QURE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
46073373
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
677330000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
244932000
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2705000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6618000
CY2021Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
10861000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4337000
CY2021Q2 qure Other Current Assets And Receivables
OtherCurrentAssetsAndReceivables
3328000
CY2020Q4 qure Other Current Assets And Receivables
OtherCurrentAssetsAndReceivables
3024000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
694224000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
258911000
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
37300000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
35200000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
38371000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32328000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26782000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26086000
CY2021Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2637000
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3361000
CY2021Q2 us-gaap Goodwill
Goodwill
525000
CY2020Q4 us-gaap Goodwill
Goodwill
542000
CY2021Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
15965000
CY2020Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
16419000
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5760000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2748000
CY2021Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
90040000
CY2020Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
81484000
CY2021Q2 us-gaap Assets
Assets
784264000
CY2020Q4 us-gaap Assets
Assets
340395000
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
16817000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3772000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23526000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18038000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5752000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5524000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
46095000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
27334000
CY2021Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
70780000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
35617000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
30534000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
30403000
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
46050250
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44777799
CY2021Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3247000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3136000
CY2021Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
104561000
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
2788000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
2711000
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1062234000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1016018000
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4595000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
9907000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-426819000
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
69156000
CY2021Q2 us-gaap Liabilities
Liabilities
150656000
CY2020Q4 us-gaap Liabilities
Liabilities
96490000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-784731000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
633608000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
243905000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
784264000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
340395000
CY2021Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
463868000
CY2020Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1535000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
464322000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
1639000
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
23178000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
23178000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32747000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28401000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
64777000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
54414000
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
17299000
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11511000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
30300000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
20583000
CY2021Q2 us-gaap Costs And Expenses
CostsAndExpenses
73224000
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
39912000
us-gaap Costs And Expenses
CostsAndExpenses
118255000
us-gaap Costs And Expenses
CostsAndExpenses
74997000
CY2021Q2 us-gaap Other Income
OtherIncome
7590000
CY2020Q2 us-gaap Other Income
OtherIncome
669000
us-gaap Other Income
OtherIncome
7942000
us-gaap Other Income
OtherIncome
1526000
CY2021Q2 us-gaap Other Expenses
OtherExpenses
226000
CY2020Q2 us-gaap Other Expenses
OtherExpenses
500000
us-gaap Other Expenses
OtherExpenses
459000
us-gaap Other Expenses
OtherExpenses
839000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
398008000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-38208000
us-gaap Operating Income Loss
OperatingIncomeLoss
353550000
us-gaap Operating Income Loss
OperatingIncomeLoss
-72671000
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
37000
CY2020Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
81000
CY2020Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-3645000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
11209000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
402726000
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-42551000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
361383000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-70550000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3258000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3471000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
399468000
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-42551000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
357912000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-70550000
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-6942000
CY2020Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
4647000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-14502000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-630000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
392526000
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37904000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
343410000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-71180000
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
8.68
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.96
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
7.82
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.59
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
8.51
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.96
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
7.67
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.59
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46037900
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44387463
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45754766
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44333460
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46929870
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44387463
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46678835
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44333460
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
295147000
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-42551000
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
4647000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2470000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5723000
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
69000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
265505000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
228690000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
399468000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-6942000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1865000
CY2021Q2 qure Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Tax Effect Prior Years
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears
2977000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
519000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7031000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
633608000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
323058000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-70550000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-630000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3402000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10078000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
265505000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
243905000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
357912000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-14502000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
29564000
qure Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Tax Effect Prior Years
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears
2977000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
911000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12792000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
49000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
633608000
us-gaap Profit Loss
ProfitLoss
357912000
us-gaap Profit Loss
ProfitLoss
-70550000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3667000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
3505000
us-gaap Share Based Compensation
ShareBasedCompensation
12792000
us-gaap Share Based Compensation
ShareBasedCompensation
10078000
qure Change In Fair Value Of Derivative Financial Instruments And Contingent Consideration
ChangeInFairValueOfDerivativeFinancialInstrumentsAndContingentConsideration
-2206000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
12279000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
908000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-539000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
1600000
qure Increase Decrease In Accounts Receivable Prepaid Expense And Other Current Assets
IncreaseDecreaseInAccountsReceivablePrepaidExpenseAndOtherCurrentAssets
3355000
qure Increase Decrease In Accounts Receivable Prepaid Expense And Other Current Assets
IncreaseDecreaseInAccountsReceivablePrepaidExpenseAndOtherCurrentAssets
-1050000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
10444000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-981000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
5486000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1332000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
375206000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-62944000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
2214000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6191000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2392000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6191000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4606000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
34603000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
30899000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1334000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
960000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3549000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
65128000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3549000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1665000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
223000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
432478000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-63778000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
247680000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
380726000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
680158000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
316948000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
677330000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
314265000
CY2021Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2828000
CY2020Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2683000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
680158000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
316948000
us-gaap Interest Paid Net
InterestPaidNet
2943000
us-gaap Interest Paid Net
InterestPaidNet
2545000
qure Increase Decrease In Accounts Payable And Accrued Liabilities Related To Non Current Assets
IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedToNonCurrentAssets
3488000
qure Increase Decrease In Accounts Payable And Accrued Liabilities Related To Non Current Assets
IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedToNonCurrentAssets
1021000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">1</b></span>General business information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">uniQure (the “Company”) was incorporated on January 9, 2012 as a private company with limited liability (<i style="font-style:italic;">besloten vennootschap met beperkte aansprakelijkheid</i>) under the laws of the Netherlands. The Company is a leader in the field of gene therapy and seeks to deliver to patients suffering from rare and other devastating diseases single treatments with potentially curative results. The Company’s business was founded in 1998 and was initially operated through its predecessor company, Amsterdam Molecular Therapeutics (AMT) Holding N.V (“AMT”). In 2012, AMT undertook a corporate reorganization, pursuant to which uniQure B.V. acquired the entire business and assets of AMT and completed a share-for-share exchange with the shareholders of AMT. Effective February 10, 2014, in connection with its initial public offering, the Company converted into a public company with limited liability (<i style="font-style:italic;">naamloze vennootschap</i>) and changed its legal name from uniQure B.V. to uniQure N.V.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 1pt 0pt 1pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company is registered in the trade register of the Chamber of Commerce (<i style="font-style:italic;">Kamer van Koophandel</i>) in Amsterdam, the Netherlands under number 54385229. The Company’s headquarters are in Amsterdam, the Netherlands, and its registered office is located at Paasheuvelweg 25, Amsterdam 1105 BP, the Netherlands and its telephone number is +31 20 240 6000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company’s ordinary shares are listed on the Nasdaq Global Select Market and trade under the symbol “QURE”.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:18pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">2.3</b></span><b style="font-weight:bold;">Use of estimates </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</p>
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23526000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18038000
qure Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Tax Effect Prior Years
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears
3000000.0
CY2021Q2 qure Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Tax Effect Prior Years
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears
3000000.0
qure Gain Loss On Recognition Of Derivatives
GainLossOnRecognitionOfDerivatives
0
CY2021Q2 qure Gain Loss On Recognition Of Derivatives
GainLossOnRecognitionOfDerivatives
0
CY2021Q2 qure Number Of Warrant Types
NumberOfWarrantTypes
2
qure Number Of Collaboration Targets
NumberOfCollaborationTargets
4
CY2021Q2 qure Collaboration Agreement Cash Payable
CollaborationAgreementCashPayable
70000000.0
CY2021Q2 qure Collaboration Agreement Cash Payable
CollaborationAgreementCashPayable
70000000.0
CY2021Q2 qure Collaboration Agreement Cash Payable
CollaborationAgreementCashPayable
70000000.0
CY2021Q2 qure Accruals For Services Provided By Vendors Not Yet Billed Current
AccrualsForServicesProvidedByVendorsNotYetBilledCurrent
16734000
CY2020Q4 qure Accruals For Services Provided By Vendors Not Yet Billed Current
AccrualsForServicesProvidedByVendorsNotYetBilledCurrent
8269000
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6792000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7687000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2082000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
357912000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-70550000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
19400000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
900000
CY2021Q2 us-gaap Other Income
OtherIncome
7600000
us-gaap Other Income
OtherIncome
7900000
CY2020Q2 us-gaap Other Income
OtherIncome
700000
us-gaap Other Income
OtherIncome
1500000
qure Employee Retention Credit Income
EmployeeRetentionCreditIncome
1300000
CY2021Q2 qure Employee Retention Credit Income
EmployeeRetentionCreditIncome
1300000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3300000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3500000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
qure Adjustments To Additional Paid In Capital Stock Issued Issuance Costs Tax Effect Prior Years
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCostsTaxEffectPriorYears
3000000.0
CY2021Q2 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
200000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
500000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2020Q2 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2021Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.008
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.010
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.25
CY2021Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.25
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
399468000
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-42551000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
357912000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-70550000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
399468000
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-42551000
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46037900
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44387463
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45754766
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44333460
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46929870
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44387463
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
46678835
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44333460
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3393724
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11600123
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3361343
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11603143
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
46300000
qure Business Combination Consideration Transferred Equity Interests Issued And Issuable Percentage
BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuablePercentage
0.25
CY2021Q2 qure Definitive Transaction Agreement Development Milestone Phase I And Ii
DefinitiveTransactionAgreementDevelopmentMilestonePhaseIAndIi
43700000
CY2021Q2 qure Definitive Transaction Agreement Development Milestone Phase Iii
DefinitiveTransactionAgreementDevelopmentMilestonePhaseIii
160000000.0

Files In Submission

Name View Source Status
0001558370-21-009246-index-headers.html Edgar Link pending
0001558370-21-009246-index.html Edgar Link pending
0001558370-21-009246.txt Edgar Link pending
0001558370-21-009246-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
qure-20210630.xsd Edgar Link pending
qure-20210630x10q.htm Edgar Link pending
qure-20210630x10q_htm.xml Edgar Link completed
qure-20210630xex10d1.htm Edgar Link pending
qure-20210630xex10d2.htm Edgar Link pending
qure-20210630xex10d2001.jpg Edgar Link pending
qure-20210630xex10d3.htm Edgar Link pending
qure-20210630xex10d3001.jpg Edgar Link pending
qure-20210630xex2d1.htm Edgar Link pending
qure-20210630xex2d1001.jpg Edgar Link pending
qure-20210630xex31d1.htm Edgar Link pending
qure-20210630xex31d2.htm Edgar Link pending
qure-20210630xex32d1.htm Edgar Link pending
qure-20210630xex3d1.htm Edgar Link pending
qure-20210630xex4d1.htm Edgar Link pending
qure-20210630_cal.xml Edgar Link unprocessable
qure-20210630_def.xml Edgar Link unprocessable
qure-20210630_lab.xml Edgar Link unprocessable
qure-20210630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending